Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03773172 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism
A Phase 2 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03773172 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 7 participants.
The verdict
NCT03773172, a Phase 2 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a Phase 2, single-center, placebo controlled, double-blind, randomized crossover study to determine the effects of MEDI6012 on the metabolism of apolipoprotein B100 (apoB100) lipoproteins in individuals with stable atherosclerotic cardiovascular disease (ASCVD).
Interventions
- DRUG Placebo
- DRUG MEDI6012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-01-31 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03773172
The ClinicalTrials.gov registry entry for NCT03773172 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03773172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03773172 about?
NCT03773172 is a clinical study titled "Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism". This is a Phase 2, single-center, placebo controlled, double-blind, randomized crossover study to determine the effects of MEDI6012 on the metabolism of apolipoprotein B100 (apoB100) lipoproteins in individuals with stable atherosclerotic cardiovascular disease (ASCVD).
What is the current status of trial NCT03773172?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2019-01-31. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT03773172?
The interventions under investigation include: Placebo (DRUG), MEDI6012 (DRUG).
Who is sponsoring clinical trial NCT03773172?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.